Research programme: antibody therapeutics - KisoJi Biotechnology
Latest Information Update: 26 Dec 2024
Price :
$50 *
At a glance
- Originator KisoJi Biotechnology
- Class Anti-inflammatories; Antibodies; Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cardiovascular disorders; Immunological disorders; Inflammation; Metabolic disorders